Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2001

01-09-2001

HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer

Authors: Gottfried Konecny, Manuel Fritz, Michael Untch, Annette Lebeau, Margrit Felber, Sandra Lude, Malgorzata Beryt, Hermann Hepp, Dennis Slamon, Mark Pegram

Published in: Breast Cancer Research and Treatment | Issue 1/2001

Login to get access
Metadata
Title
HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer
Authors
Gottfried Konecny
Manuel Fritz
Michael Untch
Annette Lebeau
Margrit Felber
Sandra Lude
Malgorzata Beryt
Hermann Hepp
Dennis Slamon
Mark Pegram
Publication date
01-09-2001
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 1/2001
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1023/A:1012226006395

Other articles of this Issue 1/2001

Breast Cancer Research and Treatment 1/2001 Go to the issue

OriginalPaper

Immunohistochemical determination of her2 expression in breast cancer from core biopsy specimens: a reliable predictor of her2 status of the whole tumor

OriginalPaper

Desferri-exochelin induces death by apoptosis in human breast cancer cells but does not kill normal breast cells

OriginalPaper

Modulation of expression of ribosomal protein L7a (rpL7a) by ethanol in human breast cancer cells

OriginalPaper

Prognostic value of TP53 gene mutation in adjuvant treated breast cancer patients

Instructions for Authors

Breast Cancer Research and Treatment

OriginalPaper

Effect of low dose tamoxifen on the insulin-like growth factor system in healthy women
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits